Pharmacokinetic rationale for the rivastigmine patch

@article{Cummings2007PharmacokineticRF,
  title={Pharmacokinetic rationale for the rivastigmine patch},
  author={Jeffrey L. Cummings and Gilbert Y. Lef{\`e}vre and Gary W. Small and Silke Appel‐Dingemanse},
  journal={Neurology},
  year={2007},
  volume={69},
  pages={S10 - S13}
}
The dual cholinesterase inhibitor rivastigmine is approved in capsule form in many countries for the symptomatic treatment of dementia associated with Alzheimer disease (AD) and Parkinson disease (PD). All orally administered cholinesterase inhibitors are associated with central cholinergic gastrointestinal side effects, particularly during the titration phase, which are believed to be caused by a rapid increase in brain acetylcholine levels after effective inhibition of the target enzymes. A… 

Figures from this paper

Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease

The apparent success of rivastigmine patch, in terms of clinical utility and patient acceptability, suggests that it may mark the next generation of dementia treatment.

Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease

The immediate switching of patients from an oral ChEI to the rivastigmine transdermal patch without a washout period was safe and well tolerated by the probable-AD patients in this study.

Rivastigmine transdermal patch: role in the management of Alzheimer's disease.

  • D. Guay
  • Medicine
    The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists
  • 2008
The TD formulation significantly reduces GI intolerance as compared with oral doses producing the same degree of systemic exposure, as a result of the lower peak plasma concentration, lower degree of peak-trough concentration fluctuation, and prolonged time to peak concentration achieved with the TD formulation.

A Review of the First Transdermal Treatment for Alzheimer’s Disease - The Rivastigmine Patch

The clinical and pharmacokinetic data that supported the development of the rivastigmine patch are reviewed, and the ways in which the use of a transdermal patch may improve the management of dementia patients in a real-life setting are discussed.

Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch

Information from patients switching from oral ChEIs to transdermal rivastigmine treatment is considered to suggest practical guidelines for patients wishing to do this, and to support recommendations for patients on high rivASTigmine capsule doses to switch directly to the 9.5 mg/24 h rivastaigmine patch.

Rationale for transdermal drug administration in Alzheimer disease

Rivastigmine is well suited to patch administration because it is a small, potent molecule that is both lipophilic and hydrophilic and may provide a promising new approach to dementia therapy.

An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine

Donepezil, rivastigmine and galantamine are the three ChEIs FDA-approved as first-line treatment for AD and the goal for the future would be to optimize the patch formulation to increase both efficacy and safety.

Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer’s disease

The aim of this review was to provide a concise, comprehensive overview of the clinically relevant safety, tolerability and efficacy information available for the rivastigmine transdermal system, which provides a viable treatment option for patients with mild to moderate AD.

Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia

The available evidence from the literature suggests that the dual inhibition of AChE and BuChE may afford additional therapeutic potential of rivastigmine in subcortical dementias (sub cortical VaD and PDD) with benefits on cognition and behavioral symptoms.
...

References

SHOWING 1-10 OF 13 REFERENCES

The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.

  • F. Inglis
  • Medicine, Biology
    International journal of clinical practice. Supplement
  • 2002
The favourable tolerability and safety profiles of these agents make them suitable first-line therapy for dementia and patients who have tolerable and/or safety problems in maintenance treatment that limit the use of donepezil or galantamine may benefit from switching to rivastigmine.

Rationale for transdermal drug administration in Alzheimer disease

Rivastigmine is well suited to patch administration because it is a small, potent molecule that is both lipophilic and hydrophilic and may provide a promising new approach to dementia therapy.

Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice‐daily Capsules in Alzheimer's Disease Patients

Plasma butyrylcholinesterase inhibition rose slowly after patch administration, whereas two distinct peaks were seen after capsule administration, and average exposure with the 10 cm2 patch was comparable to the highest capsule dose.

Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors

The knowledge base for the pharmacokinetics and pharmacodynamics of cholinesterase inhibitors continues to expand and increased information available to clinicians can optimise the use of these agents in the management of patients with Alzheimer’s disease.

Rivastigmine. A review of its use in Alzheimer's disease.

Rivastigmine is a useful option for the treatment of patients with mild to moderately severe Alzheimer's disease and, given the lack of established treatment options, it should be considered for first-line use in this population.

Pharmacokinetics of a Rivastigmine Transdermal Patch Formulation in Healthy Volunteers: Relative Effects of Body Site Application

Pharmacokinetic profiles and adhesiveness of the upper back, chest, and upper arm, coupled with low rates of erythema at these sites, suggest their suitability for clinical use.

Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.

  • G. Grossberg
  • Medicine, Biology
    Current therapeutic research, clinical and experimental
  • 2003

Inhibition of Human Cholinesterases by Drugs Used to Treat Alzheimer Disease

Development of drugs targeted toward the exclusive inhibition of one or the other cholinesterase may be important for understanding the relative importance of inhibition of BuChE and AChE in the treatment of this disease.